RASGEF1C As a Novel Prognostic Biomarker for LUAD

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 23

PMID 39714713

Authors

Jinlong Liu

Xiaoying Liu

Yingou Zeng

Di Qiao

Bin Dai

Yunlong Wu

Meng Wang

Qiang Wang

Affiliations

Soon will be listed here.

Abstract

Lung adenocarcinoma (LUAD) is a common histologic lung cancer with high morbidity and mortality, and most patients have distant metastases at diagnosis. RasGEF Domain Family Member 1C (RASGEF1C) could regulated Alzheimer's disease. However, its function in various cancers, including LUAD, is poorly understood. In the present study, we discovered that high expression of RASGEF1C in LUAD was associated with poorer prognosis, unfavorable histological features, and poorer pathological staging. In addition, RASGEF1C expression was an independent predictor of overall survival, disease specific survival, and progress free interval in patients with LUAD. High expression of RASGEF1C was linked to signaling pathways that are involved in the immune response and cell proliferation, according to KEGG enrichment analysis. Additionally, we verified that RASGEF1C was highly expressed in LUAD cell lines and that RASGEF1C knockdown dramatically decreased the capacity of LUAD cell lines to invade, migrate, and proliferate. Our research provides mechanistic insights into the function of RASGEF1C in the progression of LUAD and suggests that RASGEF1C is a prospective target for future therapy.

References

Liang W, Zhao Y, Huang W, Gao Y, Xu W, Tao J . Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). Theranostics. 2019; 9(7):2056-2070. PMC: 6485294. DOI: 10.7150/thno.28119. View

Palmeri M, Mehnert J, Silk A, Jabbour S, Ganesan S, Popli P . Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2021; 7(1):100336. PMC: 8717431. DOI: 10.1016/j.esmoop.2021.100336. View

Mizuno H, Kitada K, Nakai K, Sarai A . PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2009; 2:18. PMC: 2689870. DOI: 10.1186/1755-8794-2-18. View

Bonneville R, Krook M, Kautto E, Miya J, Wing M, Chen H . Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. 2018; 2017. PMC: 5972025. DOI: 10.1200/PO.17.00073. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

An Y, Duan H . The role of m6A RNA methylation in cancer metabolism. Mol Cancer. 2022; 21(1):14. PMC: 8753874. DOI: 10.1186/s12943-022-01500-4. View

Martin P, Leighl N . Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice. Ther Adv Med Oncol. 2017; 9(6):405-414. PMC: 5455881. DOI: 10.1177/1758834017704329. View

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Yang T . The Immune Landscape of Cancer. Immunity. 2018; 48(4):812-830.e14. PMC: 5982584. DOI: 10.1016/j.immuni.2018.03.023. View

10.

Tomczak K, Czerwinska P, Wiznerowicz M . The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015; 19(1A):A68-77. PMC: 4322527. DOI: 10.5114/wo.2014.47136. View

11.

Qi Y, Liu Z, Hong L, Li P, Ling Z . Methyltransferase-like proteins in cancer biology and potential therapeutic targeting. J Hematol Oncol. 2023; 16(1):89. PMC: 10394802. DOI: 10.1186/s13045-023-01477-7. View

12.

Li Q, Sun Y, Wang T . Epigenome-wide association study of Alzheimer's disease replicates 22 differentially methylated positions and 30 differentially methylated regions. Clin Epigenetics. 2020; 12(1):149. PMC: 7568396. DOI: 10.1186/s13148-020-00944-z. View

13.

Yang B, Wang J, Tan Y, Yuan R, Chen Z, Zou C . RNA methylation and cancer treatment. Pharmacol Res. 2021; 174:105937. DOI: 10.1016/j.phrs.2021.105937. View

14.

Aran D, Hu Z, Butte A . xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017; 18(1):220. PMC: 5688663. DOI: 10.1186/s13059-017-1349-1. View

15.

Goff S, Danforth D . The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer. Clin Breast Cancer. 2020; 21(1):e63-e73. PMC: 7775885. DOI: 10.1016/j.clbc.2020.06.011. View

16.

Namdar-Aligoodarzi P, Mohammadparast S, Zaker-Kandjani B, Talebi Kakroodi S, Jafari Vesiehsari M, Ohadi M . Exceptionally long 5' UTR short tandem repeats specifically linked to primates. Gene. 2015; 569(1):88-94. DOI: 10.1016/j.gene.2015.05.053. View

17.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

18.

Brody H . Lung cancer. Nature. 2020; 587(7834):S7. DOI: 10.1038/d41586-020-03152-0. View

19.

Bade B, Dela Cruz C . Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med. 2020; 41(1):1-24. DOI: 10.1016/j.ccm.2019.10.001. View

20.

Park D, Sung P, Kim J, Lee G, Jang J, Jung E . EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1. J Immunother Cancer. 2020; 8(1). PMC: 7206970. DOI: 10.1136/jitc-2019-000301. View